We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Abcam PLC | NASDAQ:ABCM | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 23.99 | 22.00 | 23.98 | 0 | 01:00:00 |
From May 2023 to May 2024
By Colin Kellaher
Life-sciences giant Danaher has agreed to buy Abcam, a supplier of protein consumables, in a deal carrying a total enterprise value of about $5.7 billion, including assumed debt.
Danaher on Monday said it would pay $24 a share in cash for Abcam, a scant 2.7% premium to Friday's closing price of $23.36 for the U.K.-based company.
Danaher said Abcam will operate as a standalone company and brand within its life-sciences segment, furthering its strategy to help map complex diseases and accelerate the drug-discovery process.
Washington-based Danaher said it plans to fund the deal, slated to close in mid-2024, with cash on hand and proceeds from the issuance of commercial paper.
Trading in shares of Abcam was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 28, 2023 07:58 ET (11:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Abcam Chart |
1 Month Abcam Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
